eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
19 hedge funds and large institutions have $89.7M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 18 → 19 (+1)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
48% less capital invested
Capital invested by funds: $174M → $89.7M (-$84.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Parallel Advisors
San Francisco,
California
|
+$3.6M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$2.21M |
| 3 |
State Street
Boston,
Massachusetts
|
+$90.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$56.1K |
| 5 |
PCM
Penserra Capital Management
Orinda,
California
|
+$3.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$152K |
| 2 |
Two Sigma Investments
New York
|
-$117K |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
-$28.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12K |
| 5 |
JP Morgan Chase
New York
|
-$6K |
EFTR Hedge Fund Activity: Q1 2022 in Review
19 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q1 2022, worth a combined $89.7M — down 48% from $174M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EFTR positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Parallel Advisors, opening a new position worth an estimated $3.6M. The largest seller was Morgan Stanley, cutting an estimated $152K.
- 19 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q1 2022, up from 18 in Q4 2021.
- Funds reported $89.7M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q1 2022, down 48% quarter-over-quarter.
- 3 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q1 2022 and 2 closed out, a net change of +1 holder.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q1 2022 was Parallel Advisors, an estimated $3.6M added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q1 2022 was Morgan Stanley, an estimated $152K sold.
Based on aggregated 13F filings for Q1 2022.